Lanreotide Activity and Synergy in Combination with Targeted Agents in Gastrointestinal Neuroendocrine Tumors (GI-NET): Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) in GI-NETs Isolated from Patients with Advanced Disease

#741

Introduction: Somatostatin receptor ligation can affect vascular signals, induce apoptosis and provide objective responses in some GI-NET patients.

Aim(s): We applied EVA/PCD (Nagourney. Curr Treat Rep Oncol 2006) to examine effects of the somatostatin analogue Lanreotide (Lan) on tumor specimens isolated from 35 GI-NET patients.

Materials and methods: Microspheroids were isolated from surgical specimens and exposed to Lan alone and in combination with Everolimus (Ever), Pazaponib (Paz), Sunitinib (Sun), LX1032 and Bevacizumab (Bev). Drug-induced cell death was measured by delayed loss-of-membrane-integrity and ATP-content. Lethal concentrations (LC50s) were interpolated from dose response curves. Synergy was analyzed by median effect.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Nagourney R, Evans S, Woltering E, Gomez-Panzani E,

Keywords: combination therapy,

To read the full abstract, please log into your ENETS Member account.